2seventy bio Inc (TSVT) News

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in...

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and...

Form 8-K - Current report

Form 8-K - Current report

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost...

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful...

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

2seventy bio, Inc. (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and...

Form 8-K - Current report

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (Nasdaq: TSVT), announced today the...